MCL1 and B-cell chronic lymphocytic leukemia: The SYK/JAK inhibitor cerdulatinib has also been shown to synergize with venetoclax by inhibiting the upregulation of BCL-XL and MCL-1 in CLL cells treated with CD40L and IL-4 or co-cultured with nurse-like cells (28).